|1.||Ahluwalia, Amrita: 6 articles (08/2015 - 09/2004)|
|2.||Okamoto, Ken: 6 articles (03/2015 - 04/2008)|
|3.||Hassoun, Paul M: 6 articles (01/2015 - 04/2003)|
|4.||Wright, Richard M: 5 articles (09/2013 - 04/2004)|
|5.||Damarla, Mahendra: 4 articles (11/2015 - 05/2008)|
|6.||Iwanaga, Takashi: 4 articles (04/2014 - 11/2006)|
|7.||Fini, Mehdi A: 4 articles (09/2013 - 11/2008)|
|8.||Linder, Nina: 4 articles (02/2012 - 07/2003)|
|9.||Martelin, Eeva: 4 articles (03/2009 - 12/2002)|
|10.||Ghosh, Suborno M: 3 articles (08/2015 - 06/2012)|
|1.||Pulmonary Hypertension (Ayerza Syndrome)
12/11/2012 - "Letter by Tsikas regarding article, "dietary nitrate ameliorates pulmonary hypertension: cytoprotective role for endothelial nitric oxide synthase and xanthine oxidoreductase"."
06/12/2012 - "Dietary nitrate ameliorates pulmonary hypertension: cytoprotective role for endothelial nitric oxide synthase and xanthine oxidoreductase."
06/01/2008 - "Xanthine dehydrogenase (XDH) is responsible for the pathological condition called Gout. "
12/01/1964 - "[HEPATIC XANTHINE DEHYDROGENASE AND ITS INHIBITION BY ANTI-GOUT AGENTS]."
03/01/2015 - "Mechanistic insights into xanthine oxidoreductase from development studies of candidate drugs to treat hyperuricemia and gout."
11/01/2015 - "Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase."
05/01/2011 - "To clarify the toxicological aspects of FYX-051, a xanthine oxidoreductase inhibitor, which is currently being developed as a therapeutic agent against gout and hyperuricemia, we performed the study focused on species differences in FYX-051-induced nephropathy. "
01/01/2013 - "Nearly 30 years have passed since the discovery of xanthine oxidoreductase (XOR) as a critical source of reactive species in ischemia/reperfusion injury. "
01/01/2001 - "Xanthine oxidoreductase (XOR) has been implicated in ischaemia-reperfusion injury, and increases in this enzyme have been found in plasma of patients with different illnesses. "
02/01/1998 - "In this paper, we have employed native gel electrophoresis together with activity staining to investigate the role human xanthine dehydrogenase (XD) and XO in hypoxic reperfusion injury. "
05/01/1997 - "Although xanthine oxidoreductase activity may be unmeasurably low in organs other than liver and intestine, it may be involved in reperfusion injury elsewhere because of its localization in capillary endothelial cells. "
01/01/1990 - "On the localization of xanthine oxidoreductase activity with respect to ischemia-reperfusion injury in rat tissues."
|4.||Brain Ischemia (Cerebral Ischemia)
01/01/2015 - "Evaluation of neuronal protective effects of xanthine oxidoreductase inhibitors on severe whole-brain ischemia in mouse model and analysis of xanthine oxidoreductase activity in the mouse brain."
01/01/2015 - "The Effects of Xanthine Oxidoreductase Inhibitors on Oxidative Stress Markers following Global Brain Ischemia Reperfusion Injury in C57BL/6 Mice."
12/01/1990 - "No conversion of xanthine dehydrogenase to oxidase in canine cerebral ischemia."
07/14/2009 - "The oxidation of xanthine by xanthine oxidase (XO) or xanthine dehydrogenase represents an important source of reactive oxygen species (ROS), which contribute to the damaging consequences of cerebral ischemia, inflammation, and neurodegenerative disorders. "
10/01/2007 - "Nitrite confers protection against myocardial infarction: role of xanthine oxidoreductase, NADPH oxidase and K(ATP) channels."
11/01/1994 - "An increase of the serum xanthine concentration in patients with myocardial infarction indicates a significant metabolic involvement of xanthine oxidoreductase in this disease and therefore a possible role in the development of tissue damage in the postischaemic phase due to oxygen radicals generated by the oxidase activity of this enzyme. "
10/01/2007 - "We determined the ability of nitrite and nitrate to confer protection against myocardial infarction in two rat models of ischemia/reperfusion injury and the role of xanthine oxidoreductase, NADPH oxidase, nitric oxide synthase and K(ATP) channels in mediating nitrite-induced cardioprotection. "
|1.||Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)
|3.||Uric Acid (Urate)
|4.||Adenosine Triphosphate (ATP)
|6.||Nitric Oxide Synthase (NO Synthase)
|8.||NADPH Oxidase (NAD(P)H oxidase)
|1.||Protein-Restricted Diet (Diet, Protein Restricted)
|3.||Drug Therapy (Chemotherapy)